Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/44566
Type
ArticleCopyright
Open access
Sustainable Development Goals
11 Cidades e comunidades sustentáveisCollections
- IOC - Artigos de Periódicos [12776]
Metadata
Show full item record
A GENOTYPING STUDY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 DRUG RESISTANCE IN A SMALL BRAZILIAN MUNICIPALITY
Genotipagem
Small municipalities
Vírus da imunodeficiência humana tipo 1
Subtipos
Brasil
Antiretroviral resistance
Human immunodeficiency virus type-1
Small municipalities
Subtypes
Brazil
Affilliation
Universidade Federal do Estado do Rio de Janeiro. Hospital Universitário Gaffrée e Guinle. Rio de Janeiro, RJ, Brasil / Programa Municipal de HIV/Aids de Miracema. Miracema, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Aids & Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Aids & Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Abstract
In Brazil, surveillance studies on antiretroviral drug resistance among drug-naïve and treatment-experienced
patients have focused primarily on patients living in large urban centers. As the epidemic spreads towards small
municipalities and the innermost parts of the country, it will be essential to monitor the prevalence of antiretroviral
drug resistance in these areas. We report the first survey on the prevalence of antiretroviral drug resistance in a
small Brazilian municipality. Between July 1999 and March 2005, 72 adult human immunodeficiency virus
type-1(HIV-1)-infected patients received care at the Municipal HIV/AIDS Program of the small, southeastern municipality of Miracema, state of Rio de Janeiro. A genotyping study of antiretroviral drug resistance was performed
in 54 patients. Among 27 samples from treatment-experienced patients, 9 (33.3%) harbored strains with reduced
drug susceptibility. Among these, 6 had reduced susceptibility to reverse transcriptase (RT) inhibitors and 3 to both
RT and protease inhibitors. No primary antiretroviral drug resistance was recorded among 27 drug-naïve subjects.
The relatively low prevalence of resistance mutations in the Miracema cohort argues against the concern that
resource-poor settings should not implement widespread accessibility to standard of care antiretroviral combinations due to the possibility of sub-optimal adherence leading to the emergence and spread of drug-resistant strains.
Keywords in Portuguese
Resistência antirretroviralGenotipagem
Small municipalities
Vírus da imunodeficiência humana tipo 1
Subtipos
Brasil
Keywords
GenotypingAntiretroviral resistance
Human immunodeficiency virus type-1
Small municipalities
Subtypes
Brazil
Share